We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
BIO-RAD LABORATORIES

Download Mobile App




HPV Test with Cytology Adds Little Diagnostic Value

By LabMedica International staff writers
Posted on 03 Jan 2018
Print article
Image: A photomicrograph of a cervical cancer biopsy. Many squamous cells show dark nuclei surrounded by a clear halo. These are koilocytes and indicative of human papillomavirus (HPV) infection (Photo courtesy of Newcastle University).
Image: A photomicrograph of a cervical cancer biopsy. Many squamous cells show dark nuclei surrounded by a clear halo. These are koilocytes and indicative of human papillomavirus (HPV) infection (Photo courtesy of Newcastle University).
The main goal of cervical screening programs is to detect and treat precancer before cancer develops. Human papillomavirus (HPV) testing is more sensitive than cytology for detecting precancer.

Current guidance largely supports inclusion of HPV testing, which is the more sensitive of the two tests for screening for precancers. Guidance documents have varied in their advice on cervical cancer screening, and not all recommend co-testing.

A team of scientists working with US National Cancer Institute (Rockville, MD, USA) quantified the detection of cervical precancer and cancer by co-testing compared with HPV testing alone at Kaiser Permanente Northern California (KPNC, Oakland, CA, USA), where 1,208,710 women age 30 years and older have undergone triennial cervical co-testing since 2003.They analyzed screening histories of 623 preceding cervical cancers and 5,369 precancers.

The team reported HPV testing identified more women subsequently diagnosed with cancer and precancer than cytology. HPV testing was statistically significantly more likely to be positive for cancer at any time point, except within 12 months. HPV-negative/cytology-positive results preceded only small fractions of cases of precancer (3.5%) and cancer (5.9%). These cancers were more likely to be regional or distant stage with squamous histopathology than other cases.

Given the rarity of cancers among screened women, the contribution of cytology to screening translated to earlier detection of at most five cases per million women per year. Two-thirds (67.9%) of women found to have cancer during 10 years of follow-up at KPNC were detected by the first co-test performed. The added sensitivity of co-testing versus HPV alone for detection of treatable cancer affected extremely few women.

Mark Schiffman, MD, MPH, senior investigator at the National Cancer Institute and the study’s lead author, said, “The molecular test detects the virus before the clone of cells is large enough to be readily detectable as abnormal cytology on an exfoliated cell sampling. In other words, first the HPV test turns positive, and then the cytology test is positive if the infected cells reach a size of lesion large enough to be detected when the cervix is scraped for the Pap test.” The study was published on November 14, 2017, in the Journal of the National Cancer Institute.

Related Links:
US National Cancer Institute
Kaiser Permanente Northern California

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Molecular Diagnostics

view channel
Image: A blood test could predict lung cancer risk more accurately and reduce the number of required scans (Photo courtesy of 123RF)

Blood Test Accurately Predicts Lung Cancer Risk and Reduces Need for Scans

Lung cancer is extremely hard to detect early due to the limitations of current screening technologies, which are costly, sometimes inaccurate, and less commonly endorsed by healthcare professionals compared... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: Exosomes can be a promising biomarker for cellular rejection after organ transplant (Photo courtesy of Nicolas Primola/Shutterstock)

Diagnostic Blood Test for Cellular Rejection after Organ Transplant Could Replace Surgical Biopsies

Transplanted organs constantly face the risk of being rejected by the recipient's immune system which differentiates self from non-self using T cells and B cells. T cells are commonly associated with acute... Read more

Microbiology

view channel
Image: The real-time multiplex PCR test is set to revolutionize early sepsis detection (Photo courtesy of Shutterstock)

1 Hour, Direct-From-Blood Multiplex PCR Test Identifies 95% of Sepsis-Causing Pathogens

Sepsis contributes to one in every three hospital deaths in the US, and globally, septic shock carries a mortality rate of 30-40%. Diagnosing sepsis early is challenging due to its non-specific symptoms... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.